80% of current drug applications in China failed to meet analysis requirements

Re:80% of current drug applications in China failed to meet ... by eveningcoffee on Sunday October 02, 2016 @10:58AM (#12622628)

This is good catch, but considering the history of such programs (https://en.wikipedia.org/wiki/Radio_Free_Europe/Radio_Libert...), it is that they publish rather information that has been suspended by local governments than something that has been made up.

Of course you should be cautious with what they publish, but this applies to every published information.

[ Parent | on HN ]

Re:80% of current drug applications in China failed to meet ... by brudgers on Sunday October 02, 2016 @01:03PM (#12623240)

From the RFA story:

data gathered during clinical trials were incomplete, failed to meet analysis requirements or were untraceable, the paper cited a source in the agency as saying.

Outside of China, clinical data is often not shared, suppressed when it does not support the claims, and p-value hacking is used to justify 'off-label' use. This is not usually spun as fabricated, and in commercial drug development my intuition is that 80% of proposed drugs having at least one of these features would be a plausible hypothesis

[ Parent | on HN ]